Literature DB >> 25552662

Mechanisms of C-peptide-mediated rescue of low O2-induced ATP release from erythrocytes of humans with type 2 diabetes.

Jennifer P Richards1, Elizabeth A Bowles1, Weston R Gordon1, Mary L Ellsworth1, Alan H Stephenson1, Randy S Sprague2.   

Abstract

The circulating erythrocyte, by virtue of the regulated release of ATP in response to reduced oxygen (O2) tension, plays a key role in maintaining appropriate perfusion distribution to meet tissue needs. Erythrocytes from individuals with Type 2 diabetes (DM2) fail to release ATP in response to this stimulus. However, the administration of C-peptide and insulin at a 1:1 ratio was shown to restore this important physiological response in humans with DM2. To begin to investigate the mechanisms by which C-peptide influences low O2-induced ATP release, erythrocytes from healthy humans and humans with DM2 were exposed to reduced O2 in a thin-film tonometer, and ATP release under these conditions was compared with release during normoxia. We determined that 1) low O2-induced ATP release from DM2 erythrocytes is rescued by C-peptide in the presence and absence of insulin, 2) the signaling pathway activated by C-peptide in human erythrocytes involves PKC, as well as soluble guanylyl cyclase (sGC) and 3) inhibitors of cGMP degradation rescue low O2-induced ATP release from DM2 erythrocytes. These results provide support for the hypothesis that both PKC and sGC are components of a signaling pathway activated by C-peptide in human erythrocytes. In addition, since both C-peptide and phosphodiesterase 5 inhibitors rescue low O2-induced ATP release from erythrocytes of humans with DM2, their administration to humans with DM2 could aid in the treatment and/or prevention of the vascular disease associated with this condition.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  G protein-coupled receptor 146; adenosine triphosphate; microcirculation; red blood cell; soluble guanylyl cyclase

Mesh:

Substances:

Year:  2014        PMID: 25552662     DOI: 10.1152/ajpregu.00420.2014

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  8 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

3.  Reduced deformability contributes to impaired deoxygenation-induced ATP release from red blood cells of older adult humans.

Authors:  Matthew L Racine; Frank A Dinenno
Journal:  J Physiol       Date:  2019-07-27       Impact factor: 5.182

Review 4.  Insights into the physiology of C-peptide.

Authors:  D Vejrazkova; M Vankova; P Lukasova; J Vcelak; B Bendlova
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

5.  Albumin Glycation Affects the Delivery of C-Peptide to the Red Blood Cells.

Authors:  Monica J Jacobs; Morgan K Geiger; Suzanne E Summers; Charles P DeLuca; Kurt R Zinn; Dana M Spence
Journal:  ACS Meas Sci Au       Date:  2022-03-02

Review 6.  Blood cells: an historical account of the roles of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-08-11       Impact factor: 3.765

7.  Development and Validation of a Novel LC-MS/MS Assay for C-Peptide in Human Serum.

Authors:  Benjamin Y Owusu; Hannah Pflaum; Russell Garner; North Foulon; Thomas J Laha; Andrew N Hoofnagle
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2020-12-28

Review 8.  Red blood cells in type 1 diabetes and multiple sclerosis and technologies to measure their emerging roles.

Authors:  M Geiger; E Hayter; R S Martin; D Spence
Journal:  J Transl Autoimmun       Date:  2022-08-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.